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Study objectives: High-concentration oxygen therapy is used to treat tissue hypoxia, but
hyperoxia causes lung injury. Overproduction of nitric oxide by nitric oxide synthase (NOS)
is thought to promote hyperoxic lung injury. The present study was conducted to examine
the role of inducible nitric oxide synthase (iNOS) in hyperoxic lung injury in mice.
Measurements and results: Mice were exposed to 498% oxygen for 72 h, and ONO-1714
(0.05mg/kg) (ONO) was subcutaneously administered to block iNOS. Hyperoxia signifi-
cantly increased total cell count, protein concentration, and nitrites/nitrates in the
bronchoalveolar lavage fluid and proinflammatory cytokines in the lung tissue. ONO
significantly prevented the increases in all of these variables. ONO suppressed histologic
evidence of lung injury. ONO markedly inhibited iNOS protein expression and nitrotyrosine
production in lung homogenates. After exposure to hyperoxia, alveolar epithelial cells
stained positively for 8-hydroxy-20-deoxyguanosine, a proper marker of oxidative DNA
damage by reactive oxygen species. ONO attenuated this finding.
Conclusions: NOS play important roles in the pathogenesis of hyperoxic lung injury.
Selective iNOS inhibitors may be useful for the treatment of hyperoxic lung injury.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
251 5511; fax: +81 75 251 5514.
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T. Yuba et al.794Introduction Oxygen exposureHigh concentrations of oxygen (450% O2) are used to treat
tissue hypoxia in patients with respiratory insufficiency, but
can injure the lung.1 Hyperoxic lung injury is pathophysio-
logically characterized by lung inflammation with activation
and recruitment of neutrophils and alveolar macrophages,
tissue and alveolar edema, and surfactant dysfunction.2–5
Recent studies suggest that lung inflammation is regulated
by several mediators, including reactive oxygen species,6–8
proinflammatory cytokines,9,10 and nitric oxide (NO).11,12
Regulation or inhibition of these mediators may be one
therapeutic strategy for hyperoxic lung injury.
A growing body of evidence suggests that small amounts
of NO produced by constitutive NO synthase (cNOS) have
important roles in several physiological conditions,13
whereas high levels of NO produced by inducible nitric
oxide synthase (iNOS) under inflammatory conditions such as
hyperoxic lung injury may be detrimental to the lung. NO
might promote inflammatory lung injury and form cytotoxic
species such as nitrogen dioxide by reacting with oxygen or
produce peroxynitrite by reacting with superoxide. The
nitrosative stress caused by these reactive species may
augment proinflammatory cytokine expression and induce
nitration-associated tissue injury.14–16
Studies in iNOS-deficient mice have indicated that the
extents of both endotoxin-induced lung injury and hyperoxic
lung injury are significantly milder in iNOS-deficient mice
than in wild-type mice.17,18 However, studies comparing
iNOS-deficient mice with wild-type mice have found that
iNOS induction protects against the effects of acute
exposure to hyperoxia.19 Although these studies were done
in knockout mice, it would be more clinically relevant to
investigate whether pharmacologic inhibition, not genetic
inhibition, of iNOS is beneficial in preventing the develop-
ment of hyperoxic lung injury.
Aminoguanidine (AG) is a relatively selective inhibitor of
iNOS, but its inhibitory activity is weak. ONO-1714,20 a
cyclic amidine derivative, has been shown to be more
selective for iNOS than AG.21 ONO-1714 inhibits human iNOS
with a Ki of 1.88 nM and inhibits rodent iNOS with a similar
potency in vitro.21 Against mouse iNOS, ONO-1714 is 875
times more potent than L-NMMA and 4900 times more potent
than AG.21 Recent studies have shown beneficial effects of
ONO-1714 on conditions such as sepsis-associated lung injury
and lung dysfunction during endotoxemia in various animal
models.22–25 The present study was conducted to examine
the role of iNOS in hyperoxic lung injury in mice.Materials and methods
Animals
These experiments were approved by the Institutional
Animal Care and Use Committee of Kyoto Prefectural
University of Medicine. Specific pathogen-free, C57BL/6J
8-week-old male mice (Japan SLC; Kyoto, Japan) were used
in all experiments. All mice were housed in the animal care
facility at Kyoto Prefectural University of Medicine until the
end of the experiments.Mice were exposed to 98% oxygen for 72 h in a sealed
Plexiglas chamber. The fractional inspired O2 concentration
in the chamber was monitored with an oxygen analyzer as
described previously.9 Mice exposed to room air under the
same conditions served as the sham treated group. Food and
water were available ad libitum.ONO-1714
A novel selective iNOS inhibitor, ONO-1714 (1S,5S,6R,7R)-7-
chloro-3-imino-5-methyl-2-azabicyclo [4.1.0] heptane hy-
drochloride (a fused piperidine derivative), was provided by
ONO Pharmaceutical Co., Ltd. (Osaka, Japan) and dissolved
in saline for use in this study. Mice received a subcutaneous
injection of various doses of ONO-1714 (0.03–0.1mg/kg) at
12-h intervals after oxygen exposure (0, 12, 24, 36, 48 and
60 h after oxygen exposure) (ONO-1714 group). For vehicle
control, the same volume of saline was subcutaneously
injected every 12 h (control group).Bronchoalveolar lavage
Bronchoalveolar lavage (BAL) was performed by administra-
tion of 0.5ml of sterile saline solution three times, and the
total cell counts in the BAL fluid (BALF) were determined
with a hemocytometer. Differential cell counts were
performed with the use of cytospin preparations stained
with Giemsa-type stain. (n ¼ 6 per group ) The BALF was
centrifuged at 500g for 10min at 4 1C, and the total protein
concentration in the BALF supernatant was determined by
the Bradford method. (n ¼ 6 per group).Nitrite and nitrate analysis
The BALF supernatant was thawed and mixed with methanol
(1:1, volume/volume) to precipitate protein and then
centrifuged at 104g for 20min at 4 1C. The supernatant
was applied to a nitrogen oxide analysis system (ENO-11;
EICOM; Kyoto, Japan). This system utilizes the high-
performance liquid chromatography-Griess method, and
nitrite/nitrate are measured separately (n ¼ 6 per group).Protein extraction and ELISA
To analyze proinflammatory cytokine protein in lung
extracts, lungs were frozen in liquid nitrogen and homo-
genized with 0.02M Tries Hal buffer (pH 7.4) containing
0.25M sucrose, 1M EDTA, and 5M EGTA. The homogenate
was centrifuged at 12 000 rpm for 10min. Mouse interleukin
(IL)-1b and IL-6 concentrations in the supernatant of the
lung homogenate were measured with the use of Quantikine
M mouse IL-1b and IL-6 immunoassay kits (R&D Systems;
Minneapolis, MN, USA). These parameters were measured
24, 48 and 72 h after oxygen exposure of the control group
and ONO-1714 group, and the sham treated group (n ¼ 6 per
group).
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Figure 1 Effect of treatment with ONO-1714 on nitrite and
nitrate levels in BALF after 72 h of hyperoxic exposure. Data are
given as means7SEM of six animals. #Po0.05 as compared with
the sham treated group. *Po0.05 as compared with the control
group. sham ¼ the sham treated group.
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Figure 2 Nitrite and nitrate levels in BALF 24, 48, and 72 h
after hyperoxic exposure. Data are given as means7SEM of six
animals. *Po0.05 as compared with the control group.
hrs ¼ hours.
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Nitrotyrosine is considered as a marker for peroxynitrite
formation and an indicator of nitrate stress. To identify
nitrotyrosine and iNOS, Western blotting was performed
with the use of a mouse anti-nitrotyrosine monoclonal
antibody (MONOSAN Sanbio b.v., Uden, the Netherlands) and
a rabbit anti-iNOS polyclonal antibody (Affinity Bioreagents,
Golden, CO, USA). Twenty micrograms of protein was
subjected to SDS-PAGE analysis, followed by immunoblotting
with anti-nitrotyrosine and anti-iNOS antibodies. Immunor-
eactive nitrotyrosine and iNOS proteins were visualized with
enhanced chemiluminescence (Amersham Bioscience, Pis-
cataway, NJ, USA), according to the manufacturer’s instruc-
tions (n ¼ 4 per group).
Histologic examination
For histologic examination, the lungs were removed and
fixed as described previously.26 The lungs were cut to a
thickness of 4mm and were stained with hematoxylin and
eosin (n ¼ 3 per group).
Immunohistochemistry
8-hydroxy-20-deoxyguanosine (8-OHdG), produced by the
oxidation of deoxyguanosine, is considered as the most
sensitive and potential marker of oxidative DNA damage.
The production of 8-OHdG in the lung was detected by
immunohistochemical analysis using anti-8-OHdG polyclonal
antibody (NOF Corporation, Tokyo, Japan) as described
previously.27 Deparaffinized slides were blocked with 10%
goat serum for 1 h. After blocking, anti-8-OHdG antibody
(0.5 mg/ml) was incubated with the sections for 1 h at room
temperature, followed by incubation with a biotinylated
secondary antibody and streptavidin-peroxidase conjugate.
Then, the slides were incubated with 3-amino,9-ethyl-
carbazole chromogen and counterstained with methyl green
(LAB VISION, Fremont, CA, USA) (n ¼ 3 per group).
Statistical analyses
All data are expressed as means7SEM and were compared
between groups by one-way analysis of variance. The
statistical significance of differences between groups
was assessed by the Fisher protected least-significant
difference test; Po0.05 was considered to indicate statis-
tical significance.
Results
Nitrite and nitrate levels in BALF
To determine the optimal concentration of ONO-1714, mice
were subcutaneously given various concentrations of ONO-
1714 (0.03–0.1mg/kg) under hyperoxia. The mice were
anesthetized and killed before BAL. BALF nitrite/nitrate
(NOx) levels significantly increased after hyperoxic exposure
in the saline group. Increased NOx levels after oxygen
exposure were inhibited by 0.05 and 0.1mg/kg ONO-1714(Fig. 1). After hyperoxic exposure plus treatment with 0.05
or 0.1mg/kg ONO-1714, the NOx levels in both groups were
significantly lower than that in the control group. To confirm
the duration of effect of ONO-1714, mice were given saline
solution or 0.05mg/kg ONO-1714 under hyperoxic exposure.
BAL was performed 0, 24, 48, and 72 h after oxygen
exposure. The increases in the BALF NOx levels induced by
hyperoxic exposure were significantly inhibited at 48 and
72 h by treatment with ONO-1714 at a dose of 0.05mg/kg
(Fig. 2). We therefore used 0.05mg/kg ONO-1714 for
subsequent treatment in the present study.
Cell differentiation and protein in BALF
To confirm the effects of ONO-1714 on inflammatory
cell accumulation and lung hyperpermeability induced by
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T. Yuba et al.796hyperoxia, BAL was performed 72 h after hyperoxic expo-
sure. Total protein concentration and the numbers of
neutrophils and alveolar macrophages in BALF were sig-
nificantly higher in the control group than in the sham
treated group (Fig. 3). Total protein concentration and the
numbers of neutrophils and alveolar macrophages in BALF in
the ONO-1714 (0.05mg/kg) group were significantly lower
than those in the control group.
Cytokine levels in lung tissue
In lung tissues from the control group, IL-1b levels 24, 48 and
72 h after hyperoxic exposure were significantly higher than
the corresponding levels in lung tissues from the sham
treated group, and the peal level was revealed 24 h after
hyperoxic exposure. In lung tissues from the control group,
IL-6 levels 24, 48 and 72 h after hyperoxic exposure were
significantly higher than the corresponding levels in lung
tissues from the sham treated group too, however, the peak
level was revealed 48 h after hyperoxic exposure. ONO-1714
significantly attenuated the increases in these cytokines in
almost all points of time, though in IL-6 levels in lung
tissue, there is no significant difference between the control
group and the ONO-1714 group 24 h after hyperoxic exposure
(Fig. 4).
Histology
After hyperoxic exposure, marked inflammatory cell infil-
tration was found in the interstices and air spaces of the
lung in the control group. Alveolar hemorrhage, fibrin
deposition, extravasated erythrocytes in the perivascular
interstitices of arterioles, and alveolar wall thickening were
observed (Fig. 5b). ONO-1714 markedly attenuated the
alveolar exudate and lung injury (Fig. 5c). No inflammatory
change was observed in the sham treated group (Fig. 5a).0
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Figure 3 (a) Effect of treatment with ONO-1714 on protein in BAL
ONO-1714 on alveolar macrophages in BALF after 72 h of hyperoxic ex
BALF after 72 h of hyperoxic exposure. Data are given as means7SEM
as compared with control group. sham ¼ the sham treated group; CWestern blotting for nitrotyrosine and iNOS in lung
tissues
Western blotting showed that nitrotyrosine and iNOS in lung
tissues were significantly increased by exposure of the lung
to hyperoxia. The levels of these proteins were significantly
lower in the ONO-1714 group than in the control group
(Fig. 6).
Immunohistochemistry
Immunohistochemical staining for 8-OHdG was analyzed. In
the sham treated group, nuclear staining for 8-OHdG was
barely detectable (Fig. 7a). In the control group, staining for
8-OHdG was intense (Fig. 7b). In ONO-1714 group, staining
for 8-OHdG was attenuated as compared with that in the
control group (Fig. 7c).
Discussion
Our results clearly showed that overproduction of NO was
associated with increased expression of iNOS protein in
hyperoxic lung injury. Treatment with ONO-1714, a potent,
selective inhibitor of iNOS, ameliorated the lung injury
induced by high concentrations of oxygen in mice. Nitrite
and nitrate (NOx) levels in BALF were used as an index of
pulmonary NO production in hyperoxic lung injury. To
determine the optimal dose of ONO-1714 for prevention of
this injury, we initially performed a dose-response study by
measuring NOx in BALF. Our data showed that ONO-1714 at
doses of 0.05–0.1mg/kg significantly inhibited the increase
in NOx in BALF. Ogasawara and colleagues
23 have reported
that ONO-1714 at a dose of 0.3mg/kg decreases cardiac
output and causes pulmonary vasoconstriction in normal
sheep. Okamoto and colleagues24 found that rats with septic
lung injury given ONO-1714 at a dose of 0.03mg/kg haven
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(c)
F after 72 h of hyperoxic exposure. (b) Effect of treatment with
posure. (c) Effect of treatment with ONO-1714 on neutrophils in
of six animals. #Po0.05 as compared with sham group. *Po0.05
¼ the control group; ONO ¼ ONO-1714 group.
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Figure 4 Effect of treatment with ONO-1714 on IL-1b (left) and IL-6 (right) levels in lung tissue after 24, 48 and 72 h of hyperoxic
exposure. Data are given as means7SEM of six animals. *Po0.05 as compared with the control group. sham ¼ the sham treated group;
hrs ¼ hours.
Figure 5 Hematoxylin–eosin staining of lung tissue 72 h after hyperoxic exposure (n ¼ 3 per group). (a) The sham treated group, no
inflammation. (b) The control group, marked inflammatory cell infiltration in the interstices and airspaces of lung; interstitial edema
and alveolar wall thickening are present. (c) ONO-1714 group, marked attenuation of inflammation.
A novel potent inhibitor reduces lung injury in mice 797survived longer than those given 0.01 or 0.1mg/kg. Studies
of intestinal ischemia-reperfusion injury have reported
similar findings.28 Our results and those of previous studies
suggested that 0.05mg/kg was the optimal dose for iNOS
inhibition.
Lung injuries were assessed on the basis of histological
findings and protein concentrations in BALF in the present
study. At each assessment, treatment with ONO-1714 was
found to attenuate hyperoxia-induced injuries. We also
evaluated the degree of inflammation by performing
macrophage and neutrophil counts in BALF and measuring
the concentrations of IL-1b and IL-6 in lung tissue. ONO-1714
treatment significantly inhibited the increases in cell counts
in BALF as well as the increases in cytokine concentrations inlung tissue, suggesting that iNOS or iNOS-derived NO plays a
crucial role in the recruitment of inflammatory cells and in
hyperoxia-induced cytokine production. Our findings are
supported by evidence from animal models of acute lung
injury suggesting that iNOS inhibitors and NO scavengers
down-regulate proinflammatory cytokines and reduce lung
injury.23,29
Proinflammatory cytokines may play important roles in
hyperoxic lung injury. TNF-a and IL-6 levels rise with
increasing severity of pathological findings.30 Administration
of cytokines, such as IL-1b, induces pulmonary edema and
death.31,32 Hyperoxia induces the formation of cytokines,
such as TNF-a and IL-6. Proinflammatory cytokines stimulate
the expression of iNOS33,34 and promote inflammatory
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Figure 6 Western blot analysis for the detection of (a) nitrotyrosine and (b) iNOS in lung tissue. Quantification of four different
samples for each group was performed by scanning densitometry. The values represent means7SEM (*Po0.05). sham ¼ the sham
treated group; C ¼ the control group; ONO ¼ ONO-1714 group. #Po0.05 as compared with the sham treated group. *Po0.05 as
compared with control group.
Figure 7 Immunohistochemical staining for 8-hydroxy-20-deoxyguanosine (8-OHdG) in the lung obtained from (a) the sham treated
group, (b) the control group, and (c) ONO-1714 group (n ¼ 3 per group). (a) Nuclear staining with 8-OHdG is barely detectable. (b)
The intensity and extent of immunoreactivity are prominent. (c) Nuclear staining for 8-OHdG is markedly attenuated.
T. Yuba et al.798processes. Neutrophil migration is augmented by chemo-
kines.35 Proinflammatory cytokines stimulate chemokine-
induced neutrophil chemotaxis.36,37 In our study, inhibition
of iNOS reduced IL-1b and IL-6 levels in hyperoxic lung
injury. This finding suggested that ONO-1714 prevents
activation of the proinflammatory cytokine network in
hyperoxic lung injury.
To examine in detail how ONO-1714 attenuated hyperox-
ia-induced lung injury, we assessed nitrotyrosine expression
and immunohistochemical staining of 8-OHdG. Recent
studies have suggested that nitrotyrosine is an indicator of
nitrative stress.38,39 8-OHdG is a proper marker of oxidative
DNA damage caused by reactive oxygen species. In our
study, ONO-1714 significantly reduced production of nitro-
tyrosine in lung tissue and decreased 8-OHdG immunoreac-
tivity. These data suggest that iNOS inhibition decreased
oxidative stress as well as nitrative stress.
The present study showed that increased expression of
iNOS mRNA coincided with increased NOx production in BALF,
which was significantly inhibited by ONO-1714. In mice
treated with ONO-1714, the NOx concentration in BALF
decreased. Our results are consistent with those reported byNaito et al.,28 who have found that ONO-1714 reduces both
intestinal ischemia-reperfusion injury and iNOS mRNA
expression in rats. These findings suggest that ONO-1714
protects the lung against hyperoxic-induced injury and
inhibits iNOS induction by suppressing the production of
NO from iNOS. We supposed that when NO was reduced, less
peroxynitrite and hydroxyl radical were produced. Conse-
quently, the reduction in oxidant stress by ONO-1714
induced the down-regulation of iNOS expression.
In conclusion, our results confirm that iNOS can influence
the response of lung tissues to hyperoxia and show that
pharmacologic (not genetic) inhibition of iNOS attenuates
hyperoxic lung injury. Clinically, the iNOS inhibitor, ONO-
1714, may be a useful therapeutic agent for ventilator-
induced or other forms of lung injury.Acknowledgement
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